Use of a High-Purity Factor X Concentrate in Turkish Subjects with Hereditary Factor X Deficiency: Post Hoc Cohort Subanalysis of a Phase 3 Study
Journal Title: Turkish Journal of Hematology - Year 2018, Vol 35, Issue 2
Abstract
Hereditary factor X (FX) deficiency is a rare bleeding disorder more prevalent in countries with high rates of consanguineous marriage. In a prospective, open-label, multicenter phase 3 study, 25 IU/kg plasmaderived factor X (pdFX) was administered as on-demand treatment or short-term prophylaxis for 6 months to 2 years. In Turkish subjects (n=6), 60.7% of bleeds were minor. A mean of 1.03 infusions were used to treat each bleed, and mean total dose per bleed was 25.38 IU/kg. Turkish subjects rated pdFX efficacy as excellent or good for all 84 assessable bleeds; investigators judged overall pdFX efficacy to be excellent or good for all subjects. Turkish subjects had 51 adverse events; 96% with known severity were mild/moderate, and 1 (infusionsite pain) was possibly pdFX-related. These results demonstrate that 25 IU/kg pdFX is safe and effective in this Turkish cohort (ClinicalTrials.gov identifier: NCT00930176).
Authors and Affiliations
Ahmet F. Öner, Tiraje Celkan, Çetin Timur, Miranda Norton, Kaan Kavaklı
Keywords
Related Articles
- EP ID EP364527
- DOI 10.4274/tjh.2017.0446
- Views 87
- Downloads 0
Isolated Zinc Deficiency Causing Severe Microcytosis and Sideroblastic Anemia
An Unusual Presentation of Metastatic Breast Carcinoma as Cold Autoimmune Hemolytic Anemia
Aggressive Multiple Myeloma with Unusual Morphology
Familial thrombocytopenia associated with ovarian agenesis, umbilical hernia, bicuspid aortic valve, patent ductus arteriosus and epilepsia
Primary Thrombophilia in Mexico XII: Miscarriages Are More Frequent in People with Sticky Platelet Syndrome
Objective: Sticky platelet syndrome (SPS) is an inherited condition that leads to arterial and venous thrombosis. There is scant information about the association between SPS and obstetric complications. This study aimed...